Opdualag Injection
Product Images NDC 0003-7125

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Opdualag (NDC 0003-7125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Opdualag-carton.jpg (Opdualag Carton)

OPDUALAG (nivolumab and relatlimab-rmbw) injection 240 mg and 80 mg per 20 mL (12 mg and 4 mg/mL) is shown in a carton label. The drug is for intravenous infusion only, provided in a single-dose 20 mL vial. The label includes storage instructions to refrigerate the vial and warnings not to use if the vial seal is broken or missing. Labeler is Bristol-Myers Squibb Company.*

FDA Label Image

Opdualag-figure-1.jpg (Opdualag Figure 1)

A Kaplan-Meier plot showing the probability of progression-free survival over 30 months comparing OPDUALAG and nivolumab. The vertical axis represents the probability of progression-free survival, while the horizontal axis shows time in months. The number of subjects at risk for both treatments is provided below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.